Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $22.00 | Neutral | JP Morgan |
| 12/7/2023 | $9.00 | Underperform | Exane BNP Paribas |
| 12/21/2022 | $18.00 | Buy | ROTH Capital |
| 7/25/2022 | $22.00 | Equal Weight → Underweight | Barclays |
| 1/10/2022 | $23.00 | Underweight → Equal-Weight | Barclays |
| 11/18/2021 | $23.00 | Equal-Weight | Morgan Stanley |
| 8/5/2021 | $25.00 | Neutral | Credit Suisse |
| 7/7/2021 | $23.00 | Equal-Weight → Underweight | Barclays |
Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Bank of America 2025 Virtual Animal Health Summit. Chief Financial Officer, Glenn David will address financial analysts and investors on Thursday, February 27, 2025, at 10:50 AM ET. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended December 31, 2024 (compared to the three months ended December 31, 2023) Net sales of $309.3 million, an increase of $59.3 million, or 24% Net income of $3.2 million, an increase of $1.9 million Diluted earnings per share of $0.08, an increase of $0.05 Adjusted EBITDA of $48.2 million, an increase of $18.7 million, or 64% Adjusted net income of $21.9 million, an increase of $8.5 million, or 63% Adjusted diluted
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 26, 2025, to stockholders of record at the close of business on March 5, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit w
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
SCHEDULE 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SCHEDULE 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00
Exane BNP Paribas initiated coverage of Phibro Animal Health with a rating of Underperform and set a new price target of $9.00
ROTH Capital initiated coverage of Phibro Animal Health with a rating of Buy and set a new price target of $18.00
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.
Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ -- TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended December 31, 2024 (compared to the three months ended December 31, 2023) Net sales of $309.3 million, an increase of $59.3 million, or 24% Net income of $3.2 million, an increase of $1.9 million Diluted earnings per share of $0.08, an increase of $0.05 Adjusted EBITDA of $48.2 million, an increase of $18.7 million, or 64% Adjusted net income of $21.9 million, an increase of $8.5 million, or 63% Adjusted diluted
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 26, 2025, to stockholders of record at the close of business on March 5, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit w
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its second quarter financial results on Wednesday, February 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)